

NOTIFICATION PURSUANT TO
SECTION 6 OF DSHEA

RECEIVED
NOV 13 1997

In compliance with Section 6 of the Dietary Supplement Health Education Act (DSHEA) and Rule 21 C.F.R. 101.93, this Notification is filed on behalf of the following manufacturer of **Muscle Tribe Pain Free™ with Purified Chondroitin Sulfates and Glucosamine #52432** bearing the statements set out below:

Weider Nutrition International, Inc.
2002 South 5070 West
Salt Lake City, Utah 84104

The text of each structure-function claim is as follows:

- (Statement 1) Pain Free™ dietary supplement combines the best of science and nature and was developed to support healthy joint function inactive adults.
- (Statement 2) Purified Chondroitin Sulfates help to maintain structural integrity of joints and blood vessels.
- (Statement 3) Glucosamine is used by the body to manufacture cartilage components necessary to facilitate joint health.

I, Luke R. Bucci, Ph.D., CCN, CNS, Vice President of Research at Weider Nutrition International, Inc. am authorized to certify this Notification of behalf of the Company. I certify that the information presented and contained in this Notification is complete and accurate and that the Office of Regulatory Affairs at Weider Nutrition International, Inc. has substantiation that each statement is truthful and not misleading.

DATED this 5th day of November, 199 7.

WEIDER NUTRITION INTERNATIONAL, INC.

BY:

DR. LUKE R. BUCCI
DR. LUKE R. BUCCI
Vice President of Research

975-0162

LET 8693
55723

Weider Nutrition Group
1960 South 4250 West
Salt Lake City UT 84104

STRUCTURE / FUNCTION CLAIMS

NUTRIENT: Glucosamine Complex & Chondroitin Sulfate

DATE: September 26, 1997
Document Name: sf01pain.wpd

BY: Luke R. Bucci, PhD

BRAND, CODE # & PRODUCT NAME(S): Muscle Tribe 52432 Pain Free 60t

NUTRIENT AMOUNT: 500 mg glucosamine complex & 400 mg chondroitin sulfates per capsule (3 caps/serving)

STRUCTURE/FUNCTION CLAIM:

Pain Free dietary supplement combines the best of science and nature and was developed to support healthy joint function in active adults.

Purified Chondroitin Sulfates help to maintain structural integrity of joints and blood vessels. **Glucosamine** is used by the body to manufacture cartilage components necessary to facilitate joint health.


Approved by / Date

REFERENCES:

1. Bucci LR. Glycosaminoglycans, Ch 12 in *Nutrition Applied to Injury Rehabilitation and Sports Medicine*, CRC Press, Boca Raton, FL, 1994, 177-203.
2. Prudden JF, Balassa LL. The biological activity of bovine cartilage preparations. *Sem Arth Rheum* 1974; 3(4):287-301.
3. Morrison LM, Enrick NL. Coronary heart disease: reduction of death rate by chondroitin sulfate A. *Angiology* 1973; 24:269-278.
4. Morrison LM. Therapeutic applications of chondroitin-4-sulfate. Appraisal of biological properties. *Folia Angiol* 1977; 25:225-230.
5. Morrison LM, Schjeide OA. *Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans)*, CC Thomas, Springfield, IL, 1974.
6. Morrison LM, Schjeide OA. *Arteriosclerosis. Prevention, Treatment and Regression*, CC Thomas, Springfield, IL, 1984.
7. Prino G. Pharmacological profile of Ateroid. *Mod Probl Pharmacopsychiatry* 1989; 23:68-76.
8. Santini V. A general practice trial of Ateroid 2000 in 8.776 patients with chronic senile

- cerebral insufficiency. *Mod Probl Pharmacopsychiatry* 1989; 23:95-101.
9. Kerzberg EM, Roldan EJA, Castelli G, Huberman ED. Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthritis. *Scand J Rheum* 1987; 16:377-380.
 10. Pipitone VR. Chondroprotection with chondroitin sulfate. *Drugs Exp Clin Res* 1991; 17(1):3-8.
 11. Oliviero U, Sorrentino GP, DePaola P, Tranfaglia E, D'Alessandro A, Carifi S, Porfido FA, Cerio R, Grasso AM, Policicchio D. Effects of the treatment with Matrix on elderly people with chronic articular degeneration. *Drugs Exp Clin Res* 1991; 17(1):45-52.
 12. Rovetta G. Galactosaminoglycuronoglycan sulfate (Matrix) in therapy of tibiofibular osteoarthritis of the knee. *Drugs Exp Clin Trials* 1991; 17(1):53-62.
 13. Crolle G D'Este E, Glucosamine sulfate for the management of arthrosis: a controlled clinical investigation, *Curr Res Med Opinion*, 1980; 7(2):104-109.
 14. D'Ambrosio E, Casa B, Bompani R, Scali G, Scali M, Glucosamine sulphate: a controlled clinical investigation in arthrosis, *Pharmatherapeutica*, 1981; 2(8): 504-508.
 15. Drovanti A, Bignamini AA, Rovati AL, Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled double-blind investigation, *Clin Ther*, 1980; 3(4):260-272.
 16. Karzel K, Domenjoz R, Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycan metabolism of fibroblast cultures, *Pharmacology*, 1971; 5:337-345.
 17. Pujalte JM, Llavore EP, Ylescupidéz FR, Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis, *Curr Med Res Opinion*, 1980; 7(2):110-114.
 18. Tapadinhas MJ, Rivera IC, Bignamini AA, Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal, *Pharmatherapeutica*, 1982; 3(3):157-168.
 19. Vaz AL, Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients, *Curr Med Res Opinion*, 1982; 8(3):145-149.
 20. Rovati LC, Clinical research in osteoarthritis: design and results of short-term and long-term trials with disease-modifying drugs, *Int J Tiss Reac*, 1992; 14(5):243-251.
 21. Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I, Glucosamine sulfate in osteoarthritis of the knee, *Osteoarthritis Cartilage*, 1994; 2:51-59.
 22. Muller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I, Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee, *Osteoarthritis Cartilage*, 1994; 2:61-69.